Tom Strange
Private Equity Investor bei iCON Infrastructure LLP
Aktive Positionen von Tom Strange
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
iCON Infrastructure LLP
 iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Private Equity Investor | 01.06.2023 | - |
Karriereverlauf von Tom Strange
Ehemalige bekannte Positionen von Tom Strange
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Private Equity Investor | 01.04.2022 | 01.11.2022 |
Ausbildung von Tom Strange
| University of Cambridge | Graduate Degree |
| The University of Nottingham | Undergraduate Degree |
Statistik
International
| Vereinigtes Königreich | 4 |
| Vereinigte Staaten | 2 |
Operativ
| Private Equity Investor | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
iCON Infrastructure LLP
iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Finance |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Tom Strange
- Erfahrung
